Figure 5.
RBM39 is required for progression and maintenance of ALL. (A) Western blot for RBM39 (left) and the growth curves (right) from the inducible control hairpin RNA, shRBM39.a, shRBM39.b, and shRBM39.c expressing NALM6 cells with doxycycline treatment. (B) Annexin V staining of NALM6 cells that expressed either an inducible control short hairpin RNA or shRBM39 after 72 hours. A representative example (left) and quantification of Annexin V+ cells (n = 3, right; ∗P < .05) are shown. (C) Representative bioluminescence pictures of immunocompromised animals (left) that were transplanted with luciferase-expressing NALM6 cells that were previously transduced with a lentiviral vector expressing either a control hairpin RNA, shRBM39.1, or shRBM39.2, and selected using puromycin for a period of 3 days. Quantification of tumor growth by total flux in vivo (right). ∗P < .05. (D) Survival analysis of the immunocompromised mice that received a transplant of control hairpin RNA-, shRBM39.1-, or shRBM39.2-expressing NALM6 cells. The P value (∗P < .05) was calculated using a log-rank (Mantel-Cox) test. (E) Immunocompromised animals were transplanted with Ph-like ALL PDX cells that were previously transduced with a lentiviral vector expressing either a control hairpin RNA, shRBM39.1, or shRBM39.2, and selected using puromycin for a period of 3 days. Human CD19+ cells in peripheral blood (PB) were monitored to assess disease burden. ∗P < .05. (F) Survival analysis of immunocompromised mice transplanted with the control hairpin, shRBM39.1-, or shRBM39.2-expressing Ph-like ALL PDX cells. ∗P < .05. (G-H) The total flux from each day as indicated in immunocompromised animals that were transplanted with luciferase-expressing NALM6 cells that were previously transduced with a lentiviral vector expressing either a control hairpin RNA, shRBM39.a, or shRBM39.c (G). ∗P < .05. The relative bioluminescence intensity is shown for 3 representative mice per group on day 6 (before doxycycline administration), day 13, and day 20 (after doxycycline administration) (H). (I) Survival analysis of mice transplanted with control hairpin RNA, shRBM39.a, or shRBM39.c-expressing NALM6 cells. (∗P < .05).

RBM39 is required for progression and maintenance of ALL. (A) Western blot for RBM39 (left) and the growth curves (right) from the inducible control hairpin RNA, shRBM39.a, shRBM39.b, and shRBM39.c expressing NALM6 cells with doxycycline treatment. (B) Annexin V staining of NALM6 cells that expressed either an inducible control short hairpin RNA or shRBM39 after 72 hours. A representative example (left) and quantification of Annexin V+ cells (n = 3, right; ∗P < .05) are shown. (C) Representative bioluminescence pictures of immunocompromised animals (left) that were transplanted with luciferase-expressing NALM6 cells that were previously transduced with a lentiviral vector expressing either a control hairpin RNA, shRBM39.1, or shRBM39.2, and selected using puromycin for a period of 3 days. Quantification of tumor growth by total flux in vivo (right). ∗P < .05. (D) Survival analysis of the immunocompromised mice that received a transplant of control hairpin RNA-, shRBM39.1-, or shRBM39.2-expressing NALM6 cells. The P value (∗P < .05) was calculated using a log-rank (Mantel-Cox) test. (E) Immunocompromised animals were transplanted with Ph-like ALL PDX cells that were previously transduced with a lentiviral vector expressing either a control hairpin RNA, shRBM39.1, or shRBM39.2, and selected using puromycin for a period of 3 days. Human CD19+ cells in peripheral blood (PB) were monitored to assess disease burden. ∗P < .05. (F) Survival analysis of immunocompromised mice transplanted with the control hairpin, shRBM39.1-, or shRBM39.2-expressing Ph-like ALL PDX cells. ∗P < .05. (G-H) The total flux from each day as indicated in immunocompromised animals that were transplanted with luciferase-expressing NALM6 cells that were previously transduced with a lentiviral vector expressing either a control hairpin RNA, shRBM39.a, or shRBM39.c (G). ∗P < .05. The relative bioluminescence intensity is shown for 3 representative mice per group on day 6 (before doxycycline administration), day 13, and day 20 (after doxycycline administration) (H). (I) Survival analysis of mice transplanted with control hairpin RNA, shRBM39.a, or shRBM39.c-expressing NALM6 cells. (∗P < .05).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal